ArcticZymes Technologies — Earnings Release 2013

Feb 13, 2014

Interim results Q4 and full year 2013 Biotec Pharmacon

Interim results Q4 and full year 2013 Biotec Pharmacon

Biotec Pharmacon ASA announces its results for the fourth quarter and

the full year 2013.

FOURTH QUARTER HIGHLIGHTS AND SUBSEQUENT EVENTS:

·

MHRA is finalizing the procedural review of Woulgan® Biogel as an

advanced Class III, rule 13 medical device. Although a positive outcome

is expected shortly, neither the conclusion nor the timeline for

completion of the process have been provided.

·

Application development is progressing and ArcticZymes has received a

grant of 3.9 mill NOK from the Research Council of Norway for enabling

new concepts for marine enzymes in Next Gen- and Single-Cell Sequencing.

·

ArcticZymes increased shipments of the rSAP enzyme to its key OEM

partner and is gaining traction with the Cod-UNG enzyme with smaller

diagnostic kit manufacturers

·

Results were overall stable in the fourth quarter, with losses declining

for the full year

OUTLOOK:

·

Pending positive outcome of the MHRA review, formal CE-marking of

Woulgan® Biogel will be issued by the Notified Body. This will be

followed by a limited product launch by Biotec BetaGlucans and a

scheduled market evaluation process with the international partner Smith

& Nephew

·

Biotec BetaGlucans also considers to serve major players in the

aquaculture feed market with beta-glucan ingredients to utilize its

competence and supply capabilities

·

In addition to continue the focus on the large OEM accounts and

application development, ArcticZymes will increase the number of

regional distribution partners and expects increased adoption of its

enzyme solutions in kits for use in research and diagnostics

Please find enclosed the complete interim report for Q4 and the full

year 2013.

For further information, please contact:

Svein W. F. Lien - CEO: +47 922 89 323

The company hosts a presentation of the interim results on Friday, 14

February at 08:30, at Thon Conference Vika Atrium, Munkedamsveien 45,

Oslo. It will be possible to follow the presentation as live video

webcast with log on at

www.biotec.no (http://file///H:/My%20Documents/Arbeidsnotater11/www.biote

c.no).